Faslodex in McCune Albright Syndrome - FMAS

Study identifier:D6992C00044

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome

Medical condition

Puberty, Precocious, McCune-Albright Syndrome

Phase

Healthy volunteers

Study drug

Fulvestrant

Sex

Female

Actual Enrollment

Study type

Age

1 Year - 10 Years

Date

Study Start Date: -

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1	-

Documents available

CSR-D6992C00044.pdf
Download
Trial Results Summaries
Available here

Contacts

Investigators

Principal Investigator

null null AstraZeneca Faslodex Medical Science Director, MD

AstraZeneca